project id: TCGA-BLCA; case submitter id: TCGA-FD-A3SP; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.3; rna integrity number: 7.3; age at index: 60; days to birth: -22005; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1952; age at diagnosis: 22005; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 783.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; cigarettes per day: 0.6575342465753424; pack years smoked: 12.0; is ffpe: false; composition: Not Reported; days to collection: 57; days to sample procurement: 0; initial weight: 390.0; portion submitter id: TCGA-FD-A3SP-01A-31; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 0.0; percent tumor cells: 80.0; percent tumor nuclei: 70.0;